

World Journal of *Virology*

World J Virol 2017 August 12; 6(3): 49-58





FIELD OF VISION

- 49 Additional attention to combination antiretroviral therapy-related lipodystrophy
Kobayashi N, Nakahara M, Oka M, Saeki K

ORIGINAL ARTICLE

Basic Study

- 53 Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes
Jones E, Mazirka P, McNurlan MA, Darras F, Gelato MC, Caso G

ABOUT COVER

Editorial Board Member of *World Journal of Virology*, Kun-Long Ben, PhD, Professor, Kunming Kangtao Biotechnology Company Ltd, Kunming 650106, Yunnan Province, China

AIM AND SCOPE

World Journal of Virology (World J Virol, WJV, online ISSN 2220-3249, DOI: 10.5501) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJV covers topics concerning arboviral infections, bronchiolitis, central nervous system viral diseases, DNA virus infections, encephalitis, eye infections, fatigue syndrome, hepatitis, meningitis, opportunistic infections, pneumonia, RNA virus infections, sexually transmitted diseases, skin diseases, slow virus diseases, tumor virus infections, viremia, zoonoses, and virology-related traditional medicine, and integrated Chinese and Western medicine. Priority publication will be given to articles concerning diagnosis and treatment of viral diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to WJV. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Virology is now indexed in PubMed, PubMed Central.

FLYLEAF

I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*
Proofing Editorial Office Director: *Ze-Mao Gong*

NAME OF JOURNAL

World Journal of Virology

ISSN

ISSN 2220-3249 (online)

LAUNCH DATE

February 12, 2012

FREQUENCY

Quarterly

EDITOR-IN-CHIEF

Ling Lu, MD, PhD, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, 3901 Rainbow Blvd, WHE 3020, KS 66160, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjnet.com/2220-3249/editorialboard.htm>

EDITORIAL OFFICE

Xiu-Xia Song, Director
World Journal of Virology
 Baishideng Publishing Group Inc
 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: editorialoffice@wjnet.com
 Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjnet.com>

PUBLISHER

Baishideng Publishing Group Inc
 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: editorialoffice@wjnet.com
 Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjnet.com>

PUBLICATION DATE

August 12, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<http://www.wjnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<http://www.f6publishing.com>

Basic Study

Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes

Eyone Jones, Pavel Mazirka, Margaret A McNurlan, Frank Darras, Marie C Gelato, Giuseppe Caso

Eyone Jones, Department of Surgery, Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States

Pavel Mazirka, Margaret A McNurlan, Giuseppe Caso, Department of Surgery, Stony Brook University Medical Center, Stony Brook, NY 11794, United States

Frank Darras, Department of Urology, Stony Brook University Medical Center, Stony Brook, NY 11794, United States

Marie C Gelato, Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, United States

Author contributions: Jones E contributed to data collection; McNurlan MA contributed to study design; Darras F recruited study subjects, collected surgical samples, and contributed to drafting the manuscript; Gelato MC contributed to overall study design; Caso G contributed to study design, performed the experiments; Jones E, Mazirka P, McNurlan MA and Caso G contributed to data analysis; Jones E, Mazirka P, McNurlan MA, Gelato MC and Caso G writing of the manuscript; Jones E, McNurlan MA, Gelato MC and Caso G contributed to data interpretation; all authors approved the final version of the manuscript.

Institutional review board statement: The study was reviewed and approved by the Stony Brook University Institutional Review Board. All specimens were acquired from patients after informed consent and ethical permission was obtained for participation in the study.

Conflict-of-interest statement: The authors have no conflict of interest to disclose.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and

the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Giuseppe Caso, MD, PhD, Department of Surgery, Stony Brook University Medical Center, 100 Nicolls Rd, Stony Brook, NY 11794, United States. giuseppe.caso@stonybrook.edu
Telephone: +1-631-4441790
Fax: +1-631-4448824

Received: January 28, 2017

Peer-review started: February 7, 2017

First decision: May 8, 2017

Revised: April 28, 2017

Accepted: June 6, 2017

Article in press: June 7, 2017

Published online: August 12, 2017

Abstract

AIM

To investigate the mechanism(s) by which potential effects of multi-drug highly-active antiretroviral therapy contributes to lipodystrophy syndrome.

METHODS

Preadipocytes from healthy donors were assessed for proliferation and differentiation in the presence of nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) individually and in combination. Effects on proliferation were assessed with a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay and effects on differentiation were assessed from glycerol-3-phosphate dehydrogenase (GP DH) activity and quantitation of Oil Red O staining for intracellular lipid. Data were analyzed with a randomized block ANOVA with post-hoc Fisher's Least Significant

Difference test.

RESULTS

Preadipocyte proliferation was inhibited by a combination of NNRTI + NRTI (14% at 48 h, $P < 0.001$) and PI + NRTI (19% at 48 h, $P < 0.001$) with additional suppression when ritonavir (RTV) was added (26% at 48 h). The drug combination of atazanavir (ATV) + RTV + emtricitabine (FTC) + tenofovir (TDF) had the greatest inhibitory effect on proliferation at 48 h. Preadipocyte differentiation was most significantly reduced by the efavirenz + FTC + TDF assessed either by GPDH activity (64%) or lipid accumulation (39%), $P < 0.001$. Combining NRTIs with a PI (ATV + FTC + TDF) significantly suppressed differentiation (GPDH activity reduced 29%, lipid accumulation reduced by 19%, $P < 0.01$). This effect was slightly greater when a boosting amount of RTV was added (ATV + FTC + TDF + RTV, $P < 0.001$).

CONCLUSION

Although combination antiretroviral therapy is clinically more efficacious than single drug regimens, it also has a much greater inhibitory effect on preadipocyte proliferation and differentiation.

Key words: Nucleoside reverse transcriptase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors; Pre-adipocytes; Highly active antiretroviral therapy; Lipodystrophy

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We demonstrated an *in vitro* system for evaluating potential antiretroviral regimens for adipose tissue toxicity. In general, combination regimens resulted in greater preadipocyte proliferation and differentiation inhibition than single therapies. The drug combination of atazanavir + emtricitabine + tenofovir had inhibitory effects on preadipocytes and adding ritonavir at levels equivalent to clinical boosting, increased toxicity still further.

Jones E, Mazirka P, McNurlan MA, Darras F, Gelato MC, Caso G. Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes. *World J Virol* 2017; 6(3): 53-58 Available from: URL: <http://www.wjgnet.com/2220-3249/full/v6/i3/53.htm> DOI: <http://dx.doi.org/10.5501/wjv.v6.i3.53>

INTRODUCTION

A link between highly active antiretroviral therapy (HAART) and HAART-associated lipodystrophy (HALS) has been recognized for well over a decade. HALS is associated with abnormal changes in fat distribution throughout the body, insulin resistance and altered levels of triglycerides, cholesterol and lipoproteins^[1]. These changes impact the health of an individual as

well as their quality of life and have reduced the impact of anti-HIV therapy development^[2,3]. HAART regimens with various combinations of protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI) and nonnucleoside reverse transcriptase inhibitors (NNRTI) have been associated with HALS (*e.g.*^[4-6]). Previously we reported on the *in-vitro* effects of two PIs, ritonavir (RTV) and atazanavir (ATV) on preadipocyte proliferation and adipogenesis^[7]. In the present study, we report the effects of common first-line combination regimens used in HIV treatment; efavirenz (EFV) + emtricitabine (FTC) + tenofovir (TDF), ATV + FTC + TDF and ATV + RTV + FTC + TDF, as well as their individual components, on *in-vitro* preadipocyte proliferation and differentiation.

MATERIALS AND METHODS

Patients and study design

Preadipocytes were obtained from abdominal subcutaneous fat tissue from healthy kidney donors undergoing nephrectomy. The samples were collected from 10 kidney donors (6 females, 4 males) who gave a written informed consent. All participants were HIV-seronegative, had an average age of 37 ± 4 years and a BMI of 29 ± 1 kg/m². Subjects were placed under standard general anesthesia and subcutaneous fat tissue was removed from the peri-umbilical area during nephrectomy. The specimens were then immediately placed in a sterile Hank's Buffered Salt Solution (HBSS) at pH 7.4 containing antibiotics and amphotericin. All fat samples were processed within one hour.

Once isolated, preadipocytes were tested *in vitro* for their ability to replicate and differentiate in the presence of different classes of antiretroviral drugs, which were applied individually or in combination. Fat samples from each donor were processed individually and each of the test conditions (drug combinations) were repeated with each donor sample. The selected drug combinations are recommended antiretroviral regimens for (naïve) HIV patients^[8]. These included a NNRTI-based regimen consisting of a NNRTI (EFV) and 2 NRTIs (TDF and FTC) (*i.e.*, EFV + TDF + FTC); and a PI-based regimen consisting of a PI (ATV) and 2 NRTIs (TDF and FTC) (*i.e.*, ATV + TDF + FTC). The PI-based combination was tested with or without the addition of another PI, RTV (*i.e.*, ATV + RTV + TDF + FTC), since this regimen is often recommended to boost the effects of other protease inhibitors^[9]. The following drug concentrations were used in all the experiments: EFV, 20 µmol/L; FTC, 15 µmol/L; TDF, 1 µmol/L; ATV, 10 µmol/L; RTV, 2 µmol/L. These concentrations are in the range of those observed in the plasma of patients treated with the specific antiretroviral combination regimens^[10-12]. The effects of antiretroviral medications were compared with control samples in which preadipocytes were cultured and stimulated to differentiate in the absence of antiretroviral medications.

Pre-adipocyte isolation and culture

Preadipocyte isolation and culture from subcutaneous fat biopsies were previously described^[7]. In brief, fat tissue was digested with collagenase (3 mg/mL, type II, Worthington, Lakewood, NJ) to obtain stromal cells that were then separated from mature adipocytes by centrifugation and incubated in erythrocyte lysing buffer (154 mmol/L NH₄Cl, 10 mmol/L K₂HPO₄, 1 mmol/L EDTA, pH 7.4) for 10 min at room temperature to eliminate red cells. Remaining debris was then removed by filtering cell suspension through a 70 µm nylon filter and then centrifuged. Pelleted preadipocytes were plated in a basal medium consisting of DMEM/F-12 (Gibco, Carlsbad, CA) supplemented with 10% Fetal Calf Serum (FCS), 2 mmol/L glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin (Gibco) and incubated for 16-18 h. After incubation, attached cells were extensively washed with warm PBS, removed from the plates with trypsin, suspended and counted. Preadipocytes were then seeded at a density of $5 \times 10^3/\text{cm}^2$.

To assess cell replication, cultures were incubated in untreated growth medium for 48 h after which the medium was exchanged for fresh medium (control) or medium containing drugs. Cell numbers were assessed over a 72 h period. For the assessment of differentiation, cultures were grown to confluence and differentiation was induced with serum-free medium (control) or the same medium containing antiretroviral drugs as previously described^[7,13]. Since some drugs (*i.e.*, EFV) are tightly bound to plasma albumin, 2 g/L bovine serum albumin (Sigma, St. Louis, MO) was added to differentiation medium in all control and treated groups. Medium was replaced every 72 h and differentiation assessed after 12 d.

Assessment of preadipocyte proliferation

The effect of antiretroviral drugs on preadipocyte proliferation was assessed by measuring the cell number in cultures exposed to the drugs for 48 and 72 h. Viable cell number was assessed with a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide based assay, as previously described^[7,14]. Since all cultures were plated at the same initial cell number, an increase or decrease in viable cells at 48 and 72 h was assumed to represent a change in the potential of cells to increase in number, *i.e.*, proliferate.

Assessment of preadipocyte differentiation

The differentiation of preadipocytes into mature adipocytes was estimated after 12 d by measuring the activity of the lipogenic marker enzyme glycerol-3-phosphate dehydrogenase (GPDH) and by quantifying the intracellular lipid accumulation after staining with Oil Red O.

GPDH assay: Determination of GPDH activity was based on the oxidation of NADH and reported as mU where 1 mU corresponded to the amount of enzyme

needed to oxidize 1 nmol of NADH/min as reported previously^[7].

Oil Red O staining: Cells fixed in a 10% formaldehyde solution were stained with Oil Red O, extracted with isopropanol and assessed for absorbance at 500 nm^[7].

Statistical analysis

Results are expressed as means \pm SEM. Differences between control and treated groups and among the treated groups were analyzed with a randomized block ANOVA with post-hoc Fisher's Least Significant Difference (LSD) test. *P* values < 0.05 were considered statistically significant.

RESULTS

The effect of anti-retroviral drugs, individually and in combination, was assessed for two distinct aspects of preadipocyte metabolism; namely the proliferation of preadipocytes and the ability of preadipocytes to differentiate into adipocytes.

Preadipocyte proliferation in the presence of NRTIs, NNRTIs and PIs

All individual antiretroviral drugs inhibited the proliferation of preadipocytes incubated in concentrations of the drugs comparable to the levels seen in the plasma of treated patients compared with untreated cells (control). This effect was statistically significant at 72 h (Figure 1; *P* < 0.02). The inhibition of proliferation in FTC-treated cells was apparent even at 48 h of incubation (*P* < 0.01).

All drug combinations tested significantly suppressed preadipocyte proliferation. In the presence of EFV + FTC + TDF (NNRTI + NRTIs) preadipocyte proliferation was inhibited by 14% and 26% respectively after 48 and 72 h compared to controls. Similarly, therapeutic combinations with ATV + FTC + TDF (PI + NRTIs) showed a reduction in preadipocyte growth of 19 % at 48 h, and of 30% at 72 h (Figure 1, *P* < 0.001). When RTV was added to ATV + FTC + TDF, as it is clinically known to boost other PIs, the inhibitory effect was more noticeable, with a suppression in proliferation of 26% and 37% respectively after 48 and 72 h compared to controls (Figure 1, *P* < 0.001).

The inhibition of proliferative activity of preadipocytes in multi-drug combinations was more severe than the inhibition of proliferation observed with the individual component drugs in some cases, but not all. In the combination EFV + FTC + TDF, suppression of proliferation was greater than the suppression observed when EFV and TDF were used individually (*P* < 0.02), but there was not an additional effect when EFV + FTC + TDF combination was compared to FTC treatment alone (*P* = NS). Combining ATV + FTC + TDF or ATV + RTV + FTC + TDF increased the inhibition of adipocyte proliferation to a greater extent than treatment with the same concentration of the individual drugs both at 48 (*P* < 0.05) and 72 h (*P* < 0.01).




Figure 1 Pre-adipocyte proliferation in the presence of individual drugs or drug combinations for 48 h (A) and 72 h (B) (MTT test). The results are expressed as percent values of control cultures. Mean ± SEM, *n* = 7. Significantly different from control, ^a*P* ≤ 0.05. EFV: Efavirenz; FTC: Emtricitabine; TDF: Tenofovir; ATV: Atazanavir.




Figure 2 Effect of individual drugs or drug combinations on differentiation of human preadipocytes. Differentiation was assessed after 12 d by measuring the glycerol-3-phosphate dehydrogenase activity (A), and Oil Red O staining (B). All results are expressed as percent values of control cultures. Mean ± SEM, *n* = 9. Significantly different from control, ^a*P* ≤ 0.05. EFV: Efavirenz; FTC: Emtricitabine; TDF: Tenofovir; ATV: Atazanavir.

Of the three multi-drug regimens, the drug combination ATV + RTV + FTC + TDF had a more suppressive effect on proliferation of preadipocytes than the other multi-drug regimens at 48 h (*P* < 0.02). At 72 h, the combination, ATV + RTV + FTC + TDF, was not statistically significantly different from ATV + FTC + TDF but was significantly different from EFV + FTC + TDF (*P* = 0.05).

Preadipocyte differentiation in the presence of NRTIs, NNRTIs and PIs

Preadipocyte differentiation, in the presence of anti-retroviral drugs, was assessed by 2 different techniques, one involved measuring the enzymatic activity of GPDH and the other involved quantifying intracellular lipid accumulation after staining with Oil Red O. The two techniques produced comparable results (Figure 2).

EFV had a profound inhibitory effect on preadipocyte differentiation (Figure 2). Both GPDH activity and lipid

accumulation were greatly reduced in cells treated with EFV compared to controls (Figure 2, *P* < 0.001). Of the other anti-retroviral drugs tested, only TDF appeared to have an effect on intracellular lipid accumulation, which tended to be lower when cells were treated with TDF (*P* = 0.06). Preadipocyte differentiation in the presence of remaining individual drugs did not differ from controls (Figure 2).

Figure 2 demonstrates that, preadipocyte differentiation was significantly reduced when the anti-retroviral drugs were used in combination compared to untreated cultures. Compared to control cells, the EFV + FTC + TDF (NNRTI + NRTIs) combination showed the most suppressive effect on differentiation with GPDH activity and lipid accumulation 64% and 39% lower respectively (Figure 2, *P* < 0.001). Combining NRTIs with a PI (ATV + FTC + TDF) inhibited GPDH activity by 29% and lipid accumulation by 19% compared to controls (Figure 2, *P* < 0.01). This effect was slightly

greater when a boosting amount of RTV was added (ATV + FTC + TDF + RTV, Figure 2, $P < 0.001$).

The inhibitory effect of a multi-drug combination NNRTI and NRTI (EFV + FTC + TDF) was also compared to the suppression in differentiation observed with the anti-retroviral medications individually. Suppression with the combination resulted in a greater reduction in preadipocyte differentiation than either FTC or TDF alone ($P < 0.001$). However, suppression of differentiation with the combination of EFV + FTC + TDF was comparable in magnitude to treatment with EFV alone suggesting EFV was accountable for most of the reduction in differentiation observed with the combination regimen (Figure 2). The two multi-drug regimens containing PI + NRTI were also examined relative to the incubations with the individual medications. The multi-drug combinations containing PIs had greater inhibitory effects on differentiation than treatment with the same concentration of each individual drug (Figure 2, $P < 0.003$), with the exception of TDF.

The multi-drug regimens have also been compared with each other. The combination with NNRTI and NRTI (EFV, FTC, TDF) reduced differentiation to a greater extent than either of the two regimens with PI + NRTI, whether assessed as either GPDH activity ($P < 0.001$) or intracellular lipid accumulation ($P < 0.02$).

DISCUSSION

There is no doubt that the etiology of HIV/HAART-associated lipodystrophy syndrome is multi-factorial, but antiretroviral medications contribute to the condition. This *in vitro* technique, with primary cultures of preadipocytes isolated from healthy subjects, provides a way of assessing effects of single and combination drug regimens on preadipocyte proliferation and differentiation; and consequently, on the potential of drug regimens to contribute to HALS. The antiretroviral medications currently in use have profound effects on both preadipocyte proliferation and differentiation.

All of the antiretroviral agents tested inhibited preadipocyte proliferation. Individually, the NRTI, FTC, had a more pronounced effect on preadipocyte proliferation than the NRTI, TDF; the NNRTI, EFV; or the PIs ATV or RTV (Figure 1). While in general combinations of anti-retroviral drugs were more toxic than the individual drugs, this was not true for combinations containing FTC. The addition of TDF (another NRTI) and EFV (a NNRTI) to emtricitabine did not produce any greater toxicity than was observed with EFV alone. However, multidrug regimens containing PIs in combination with NRTI (ATV + FTC + TDF and ATV + RTV + FTC + TDF) resulted in further suppression of proliferation. Having previously demonstrated that RTV does not suppress preadipocyte proliferation at levels comparable to those used for boosting^[7], this study indicates that adding RTV to a combination of ATV, TDF and FTC does increase toxicity (Figure 1). Clearly, the toxicity of individual antiretrovirals can be affected by concurrent antiretroviral administration.

In contrast to preadipocyte proliferation, it is the NNRTI EFV that has the most profound effect on preadipocyte differentiation, an effect that has been reported previously^[15,16]. Combining EFV with NRTIs (EFV + FTC + TDF) does not result in any greater suppression. Regimens containing PIs and NRTIs (ATV + FTC + TDF and ATV + RTV + FTC + TDF) are not as toxic as those containing EFV. However, the multi-drug combinations containing PIs suppressed differentiation to a greater extent than the use of any drug individually. This study highlights the importance of assessing both the effects on the proliferation of preadipocytes and the differentiation of preadipocytes into mature adipocytes since multi-drug regimens affect them differently.

In conclusion, antiretroviral medications affect not only the differentiation of preadipocyte into mature adipocytes, these drugs also affect the proliferation of preadipocytes and can, therefore, impact on the number of preadipocytes that are available. While FTC has the most profound effect on preadipocyte proliferation, it is EFV that has the greatest impact on differentiation. Combinations of antiretroviral medications, which have no impact when used individually, increase the toxicity for preadipocytes.

COMMENTS

Background

Highly active antiretroviral therapy (HAART) regimens with various combinations of protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI) and nonnucleoside reverse transcriptase inhibitors (NNRTI) have long been linked to HAART-associated lipodystrophy syndrome (HALS). Once HALS is manifest, it is difficult to reverse. There is a need to develop ways of assessing drug combinations for the potential to contribute to HALS.

Research frontiers

The effect of individual anti-retroviral drugs have been studied *in vitro*, but this is the first report of the effect of drug combinations assessed at clinically relevant concentrations. The differential effects on preadipocyte proliferation and differentiation were also assessed, providing important mechanistic information.

Innovations and breakthroughs

The study demonstrates that replacing ritonavir-based regimens with the clinically more acceptable protease inhibitor, atazanavir, does not eliminate the potential for toxic effects on adipose tissue. In addition, adding ritonavir at "boosting" levels to regimens containing nucleoside reverse transcriptase inhibitors and non-reverse transcriptase inhibitors also increases the lipo-toxic potential of these antiretroviral combinations.

Applications

Although combination antiretroviral therapy is clinically more efficacious than single drug regimens, the combination regimens also have the potential to contribute to adipose tissue toxicity through effects of preadipocyte replication and differentiation. The study also illustrates the value of an *in vitro* system for screening drug combinations for potential adipose tissue toxicity.

Terminology

HALS is a condition that is characterized by loss of subcutaneous fat, particularly in the face, buttocks, arms and legs. Antiretroviral therapy typically includes a combination of drugs with different mechanisms of action including NRTIs, NNRTIs, and PIs. These drug classes have the potential for differential effects on adipose tissue and the effect of combination therapy may be greater than the individual drugs alone. This study also investigated the mechanisms by which antiretroviral drugs can contribute to the loss of adipose tissue;

an inability of preadipocytes to proliferate reduces the potential number of precursor cells for the formation of adipose tissue, the inability of pre-adipocytes to differentiation reduces the formation of adipose tissue by arresting precursor cells in an undifferentiated state.

Peer-review

This manuscript is worth publishing, reporting the synergistic or cooperative effects of anti-HIV agents on inhibiting adipogenesis by performing *in vitro* experiments using human materials. It will help us to recognize the importance to take extra caution in executing HAART.

REFERENCES

- 1 **Guaraldi G**, Stentarelli C, Zona S, Santoro A. HIV-associated lipodystrophy: impact of antiretroviral therapy. *Drugs* 2013; **73**: 1431-1450 [PMID: 24002702 DOI: 10.1007/s40265-013-0108-1]
- 2 **Lake JE**, Wohl D, Scherzer R, Grunfeld C, Tien PC, Sidney S, Currier JS. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. *AIDS Care* 2011; **23**: 929-938 [PMID: 21767228 DOI: 10.1080/09540121.2010.543885]
- 3 **Quintas RC**, de França ER, de Petribú KC, Ximenes RA, Quintas LF, Cavalcanti EL, Kitamura MA, Magalhães KA, Paiva KC, Filho DB. Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life. *Int J Dermatol* 2014; **53**: 497-502 [PMID: 24602032 DOI: 10.1111/jid.12400]
- 4 **Domingo P**, Estrada V, López-Aldeguer J, Villaroya F, Martínez E. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. *AIDS Rev* 2012; **14**: 112-123 [PMID: 22627607]
- 5 **Martin A**, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. *PLoS One* 2013; **8**: e77138 [PMID: 24204757 DOI: 10.1371/journal.pone.0077138]
- 6 **Minami R**, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. *J Infect Chemother* 2011; **17**: 183-188 [PMID: 20706762 DOI: 10.1007/s10156-010-0101-5]
- 7 **Caso G**, Mileva I, McNurlan MA, Mynarcik DC, Darras F, Gelato MC. Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation. *Antiviral Res* 2010; **86**: 137-143 [PMID: 20153378]

- 8 **Panel on Antiretroviral Guidelines for Adults and Adolescents.** Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Section accessed on March 18, 2015 (Table 6). Available from: URL: <http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf>
- 9 **Zeldin RK**, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. *J Antimicrob Chemother* 2004; **53**: 4-9 [PMID: 14657084 DOI: 10.1093/jac/dkh029]
- 10 **Clay PG**, Taylor TA, Glaros AG, McRae M, Williams C, McCandless D, Oelklaus M. “One pill, once daily”: what clinicians need to know about Atripla trade mark. *Ther Clin Risk Manag* 2008; **4**: 291-302 [PMID: 18728842]
- 11 **Kiser JJ**, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. *Antimicrob Agents Chemother* 2008; **52**: 631-637 [PMID: 18025112 DOI: 10.1128/AAC.00761-07]
- 12 **von Hentig N**, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. *Eur J Clin Pharmacol* 2007; **63**: 935-940 [PMID: 17665183 DOI: 10.1007/s00228-007-0344-y]
- 13 **Tchkonja T**, Giorgadze N, Pirtskhalava T, Tchoukalova Y, Karagiannides I, Forse RA, DePonte M, Stevenson M, Guo W, Han J, Waloga G, Lash TL, Jensen MD, Kirkland JL. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. *Am J Physiol Regul Integr Comp Physiol* 2002; **282**: R1286-R1296 [PMID: 11959668]
- 14 **Caso G**, McNurlan MA, McMillan ND, Eremin O, Garlick PJ. Tumour cell growth in culture: dependence on arginine. *Clin Sci (Lond)* 2004; **107**: 371-379 [PMID: 15157183]
- 15 **El Hadri K**, Glorian M, Monsempes C, Dieudonné MN, Pecquery R, Giudicelli Y, Andreani M, Dugail I, Fève B. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. *J Biol Chem* 2004; **279**: 15130-15141 [PMID: 14722061 DOI: 10.1074/jbc.M312875200]
- 16 **Gallego-Escuredo JM**, Del Mar Gutierrez M, Diaz-Delfin J, Domingo JC, Mateo MG, Domingo P, Giral M, Villarroya F. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. *Curr HIV Res* 2010; **8**: 545-553 [PMID: 21073442]

P- Reviewer: Saeki K, Shen WJ **S- Editor:** Song XX **L- Editor:** A
E- Editor: Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

